BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 15173006)

  • 1. Genome-wide identification of genes conferring resistance to the anticancer agents cisplatin, oxaliplatin, and mitomycin C.
    Wu HI; Brown JA; Dorie MJ; Lazzeroni L; Brown JM
    Cancer Res; 2004 Jun; 64(11):3940-8. PubMed ID: 15173006
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Specificity of platinum-DNA adduct repair.
    Chaney SG; Vaisman A
    J Inorg Biochem; 1999 Oct; 77(1-2):71-81. PubMed ID: 10626357
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficient nucleotide excision repair of cisplatin, oxaliplatin, and Bis-aceto-ammine-dichloro-cyclohexylamine-platinum(IV) (JM216) platinum intrastrand DNA diadducts.
    Reardon JT; Vaisman A; Chaney SG; Sancar A
    Cancer Res; 1999 Aug; 59(16):3968-71. PubMed ID: 10463593
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acquired resistance to oxaliplatin is not directly associated with increased resistance to DNA damage in SK-N-ASrOXALI4000, a newly established oxaliplatin-resistant sub-line of the neuroblastoma cell line SK-N-AS.
    Saintas E; Abrahams L; Ahmad GT; Ajakaiye AM; AlHumaidi AS; Ashmore-Harris C; Clark I; Dura UK; Fixmer CN; Ike-Morris C; Mato Prado M; Mccullough D; Mishra S; Schöler KM; Timur H; Williamson MD; Alatsatianos M; Bahsoun B; Blackburn E; Hogwood CE; Lithgow PE; Rowe M; Yiangou L; Rothweiler F; Cinatl J; Zehner R; Baines AJ; Garrett MD; Gourlay CW; Griffin DK; Gullick WJ; Hargreaves E; Howard MJ; Lloyd DR; Rossman JS; Smales CM; Tsaousis AD; von der Haar T; Wass MN; Michaelis M
    PLoS One; 2017; 12(2):e0172140. PubMed ID: 28192521
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Unique properties of DNA interstrand cross-links of antitumor oxaliplatin and the effect of chirality of the carrier ligand.
    Kasparkova J; Vojtiskova M; Natile G; Brabec V
    Chemistry; 2008; 14(4):1330-41. PubMed ID: 18022972
    [TBL] [Abstract][Full Text] [Related]  

  • 6. DNA polymerase ζ is a major determinant of resistance to platinum-based chemotherapeutic agents.
    Sharma S; Shah NA; Joiner AM; Roberts KH; Canman CE
    Mol Pharmacol; 2012 Jun; 81(6):778-87. PubMed ID: 22387291
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of endonucleases XPF and XPG in nucleotide excision repair of platinated DNA and cisplatin/oxaliplatin cytotoxicity.
    Graf N; Ang WH; Zhu G; Myint M; Lippard SJ
    Chembiochem; 2011 May; 12(7):1115-23. PubMed ID: 21452186
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Monofunctional platinum-DNA adducts are strong inhibitors of transcription and substrates for nucleotide excision repair in live mammalian cells.
    Zhu G; Myint M; Ang WH; Song L; Lippard SJ
    Cancer Res; 2012 Feb; 72(3):790-800. PubMed ID: 22180496
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multiple states of stalled T7 RNA polymerase at DNA lesions generated by platinum anticancer agents.
    Jung Y; Lippard SJ
    J Biol Chem; 2003 Dec; 278(52):52084-92. PubMed ID: 14534300
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human colon cancer cells surviving high doses of cisplatin or oxaliplatin in vitro are not defective in DNA mismatch repair proteins.
    Sergent C; Franco N; Chapusot C; Lizard-Nacol S; Isambert N; Correia M; Chauffert B
    Cancer Chemother Pharmacol; 2002 Jun; 49(6):445-52. PubMed ID: 12107548
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Altered drug sensitivities to anticancer agents in radiation-sensitive DNA repair deficient yeast mutants.
    Abe H; Wada M; Kohno K; Kuwano M
    Anticancer Res; 1994; 14(5A):1807-10. PubMed ID: 7531413
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro studies on the mechanisms of oxaliplatin resistance.
    Hector S; Bolanowska-Higdon W; Zdanowicz J; Hitt S; Pendyala L
    Cancer Chemother Pharmacol; 2001 Nov; 48(5):398-406. PubMed ID: 11761458
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oxaliplatin, tetraplatin, cisplatin, and carboplatin: spectrum of activity in drug-resistant cell lines and in the cell lines of the National Cancer Institute's Anticancer Drug Screen panel.
    Rixe O; Ortuzar W; Alvarez M; Parker R; Reed E; Paull K; Fojo T
    Biochem Pharmacol; 1996 Dec; 52(12):1855-65. PubMed ID: 8951344
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of hMLH1, hMSH3, and hMSH6 defects in cisplatin and oxaliplatin resistance: correlation with replicative bypass of platinum-DNA adducts.
    Vaisman A; Varchenko M; Umar A; Kunkel TA; Risinger JI; Barrett JC; Hamilton TC; Chaney SG
    Cancer Res; 1998 Aug; 58(16):3579-85. PubMed ID: 9721864
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Base excision repair of reactive oxygen species-initiated 7,8-dihydro-8-oxo-2'-deoxyguanosine inhibits the cytotoxicity of platinum anticancer drugs.
    Preston TJ; Henderson JT; McCallum GP; Wells PG
    Mol Cancer Ther; 2009 Jul; 8(7):2015-26. PubMed ID: 19567822
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recognition of platinum-DNA damage by poly(ADP-ribose) polymerase-1.
    Zhu G; Chang P; Lippard SJ
    Biochemistry; 2010 Jul; 49(29):6177-83. PubMed ID: 20550106
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multiple repair pathways mediate tolerance to chemotherapeutic cross-linking agents in vertebrate cells.
    Nojima K; Hochegger H; Saberi A; Fukushima T; Kikuchi K; Yoshimura M; Orelli BJ; Bishop DK; Hirano S; Ohzeki M; Ishiai M; Yamamoto K; Takata M; Arakawa H; Buerstedde JM; Yamazoe M; Kawamoto T; Araki K; Takahashi JA; Hashimoto N; Takeda S; Sonoda E
    Cancer Res; 2005 Dec; 65(24):11704-11. PubMed ID: 16357182
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative chemogenomics to examine the mechanism of action of dna-targeted platinum-acridine anticancer agents.
    Cheung-Ong K; Song KT; Ma Z; Shabtai D; Lee AY; Gallo D; Heisler LE; Brown GW; Bierbach U; Giaever G; Nislow C
    ACS Chem Biol; 2012 Nov; 7(11):1892-901. PubMed ID: 22928710
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Saccharomyces cerevisiae orthologue of the human protein phosphatase 4 core regulatory subunit R2 confers resistance to the anticancer drug cisplatin.
    Hastie CJ; Vázquez-Martin C; Philp A; Stark MJ; Cohen PT
    FEBS J; 2006 Jul; 273(14):3322-34. PubMed ID: 16857015
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cellular and molecular aspects of drugs of the future: oxaliplatin.
    Di Francesco AM; Ruggiero A; Riccardi R
    Cell Mol Life Sci; 2002 Nov; 59(11):1914-27. PubMed ID: 12530522
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.